Clinical trial
Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic…
NCT00068211 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00068211 |
|---|---|
| Title | Study of ILX651 in Patients With Inoperable Locally Advanced or Metastatic Melanoma |
| Official title | A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma. |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | ILX651 |
| Start date | Aug 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Sep 11, 2003 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: